Form 13D/A Silexion Therapeutics Corp For: 23 June
- Investing.com
- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Silexion Therapeutics Corp (SLXN)
Track today's live Silexion Therapeutics (SLXN) share price, performance and key data on this page with our current NASDAQ:SLXN stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the Silexion Therapeutics share price on the NASDAQ exchange. Use the dropdown to switch exchange for the SLXN share price, head to our technical summary section, which provides analysis on Silexion Therapeutics share price buy/sell indicators using real-time data (or discuss the Silexion Therapeutics (SLXN) stock price today with other investors in the Silexion Therapeutics NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ:SLXN share price (ISIN: KYG1281K1489) to enhance your trading decisions with our free investment tools and resources.
What Is the Silexion Therapeutics Corp Share Price Today?
The Silexion Therapeutics share price today is 2.700.
What Is the Stock Symbol for Silexion Therapeutics Corp
The stock symbol (or 'ticker') for Silexion Therapeutics Corp is "SLXN."
What Stock Exchange Does Silexion Therapeutics Corp Trade On?
Silexion Therapeutics Corp is listed and trades on the NASDAQ stock exchange.
Is Silexion Therapeutics Corp a Good Stock to Buy?
Determining whether Silexion Therapeutics (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current NASDAQ:SLXN share price (ISIN: KYG1281K1489) to enhance your trading decisions with our free investment tools and resources.
What Is the Silexion Therapeutics Corp Share Price Today?
The Silexion Therapeutics share price today is 2.700.
What Is the Stock Symbol for Silexion Therapeutics Corp
The stock symbol (or 'ticker') for Silexion Therapeutics Corp is "SLXN."
What Stock Exchange Does Silexion Therapeutics Corp Trade On?
Silexion Therapeutics Corp is listed and trades on the NASDAQ stock exchange.
Is Silexion Therapeutics Corp a Good Stock to Buy?
Determining whether Silexion Therapeutics (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.529
2.850
52 wk Range
2.310
223.600
SLXN is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.5292.850
52 wk Range
2.310223.600
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
SLXN Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
60.000
Upside
+2,122.22%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- Form 13D/A Silexion Therapeutics Corp For: 23 June
- Investing.com
- Form 13D/A Silexion Therapeutics Corp For: 29 May
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Neutral
Analyst Ratings
2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 60.000
(+2,122.22% Upside)
Earnings
Latest Release
18/05/2026
EPS / Forecast
-8.50 / --
Revenue / Forecast
-- / --
Compare SLXN to Peers and Sector
Metrics to compare | SLXN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSLXNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.1x | −3.7x | −0.4x | |
PEG Ratio | 0.00 | 0.00 | 0.00 | |
Price/Book | 3.9x | 1.0x | 2.6x | |
Price / LTM Sales | - | 7.0x | 3.0x | |
Upside (Analyst Target) | - | 755.3% | 55.7% | |
Fair Value Upside | Unlock | 0.9% | 8.1% | Unlock |
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. Silexion Therapeutics Corp has collaboration with Evonik Corporation for the development of an advanced siRNA formulation to enhance cancer treatment. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Silexion Therapeutics (NASDAQ: SLXN) Share Price Today?
The Silexion Therapeutics stock price today is 2.700 USD.
What Stock Exchange Does Silexion Therapeutics (SLXN) Trade On?
Silexion Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Silexion Therapeutics?
The stock symbol (also called a 'ticker') for Silexion Therapeutics is "SLXN."
What Is the Current Silexion Therapeutics Market Capitalisation?
As of today, Silexion Therapeutics (NASDAQ: SLXN) market cap is 1.130M USD.
What Is Silexion Therapeutics's (SLXN) Earnings Per Share (TTM)?
The Silexion Therapeutics EPS is currently -63.781 (Trailing Twelve Months).
When Is the Next Silexion Therapeutics Earnings Date?
Silexion Therapeutics's next earnings report will be released on 18/08/2026.
Is SLXN a Buy or Sell From a Technical Analyst Perspective?
Based on today's Silexion Therapeutics moving averages and other technical indicators, the daily buy/sell signal for SLXN stock is Strong Sell.
How Many Times Has Silexion Therapeutics Stock Split?
Silexion Therapeutics has split 3 times. (See the SLXN stock split history page for full effective split date and price information.)
How Many Employees Does Silexion Therapeutics Have?
Silexion Therapeutics has 14 employees, based on their latest Companies House report.
What is the current trading status of Silexion Therapeutics (NASDAQ: SLXN)?
As of 25/06/2026, Silexion Therapeutics (SLXN) is trading at a share price of 2.700 USD, with a previous close of 2.700 USD. The stock has fluctuated within a day range of 2.529 USD to 2.850 USD, while its 52-week range spans from 2.310 USD to 223.600 USD.
What Is Silexion Therapeutics (SLXN) Price Target According to Analysts?
The average 12-month price target for Silexion Therapeutics is 60.000 USD, with a high estimate of 60 USD and a low estimate of 60 USD. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +2,122.22% Upside potential.
What Is the SLXN Premarket Price?
SLXN's last pre-market stock price is 2.690 USD. The pre-market share volume is 240.000, and the stock has decreased by -0.010, or -0.370%.
What Is the SLXN After Hours Price?
SLXN's last after hours stock price is 2.690 USD, the stock has decreased by -0.010, or -0.370%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.